Archive for the ‘Patient information’ Category

A prescription of hope

Author: Guest, 08/29/17

By Brian Sladek I am honoured to have my blog be just one of several covering this topic as part of Signal’s second annual blog carnival on the theme ‘Right to Try.’ Please click here to read what other bloggers think of this. As a patient, I don’t care about percentages. According to a recent SEER…Read more

An ivory tower perspective of the right-to-try movement: We need to balance the equation

Author: Guest, 08/29/17

Patrick Bedford is the Senior Manager of Clinical Translation and Regulatory Affairs at CCRM. He holds a Master’s Degree in Bioethics and Health Law, and a Regulatory Affairs Certificate. Patrick has spent over 11 years applying federal regulations to emerging biotechnologies in Canada. Follow him on LinkedIN. Do desperate times call for desperate measures in the context…Read more

Right Turn: ‘Right to try’ state of affairs in U.S.

Author: Stacey Johnson, 08/25/17

On Tuesday, August 29, Signals is hosting a blog carnival on the topic Right to Try. Before you read the perspectives of the contributing bloggers, here’s what President Trump thinks about the legislation and the Goldwater Institute’s reaction. It’s the Institute that took on this cause in the first place. Earlier this month, the U.S….Read more

Weighing in on a controversial topic

Author: Stacey Johnson, 08/23/17

We are less than one week away from Signals’ second blog carnival! Last month I promised to reveal the topic and the participants. I also hinted that this year’s topic might strike some readers as controversial. Given that a few invited bloggers declined to participate, I’d have to say that’s the case. So although our…Read more

Improving our understanding of how aging happens

Author: Stacey Johnson, 08/03/17

Dr. William Stanford, The Ottawa Hospital, is working with colleagues to help patients with Hutchinson-Gilford progeria syndrome (HGPS). They have shown that cells from individuals with HGPS – also called progeria – can be genetically reprogrammed, turning them into stem cells that don’t show any signs of aging. According to the news release issued by…Read more

The stem cell community’s blog carnival is back!

Author: Stacey Johnson, 07/27/17

Last August, Signals hosted its first blog carnival and it was so much fun, we’re doing it again. Missed it? No idea what a blog carnival involves? The way I explained it last year is like this: A blog carnival is essentially an online blogging “party” with many guests who all blog on the same…Read more

Right Turn: Clinical trials – one solution to unapproved stem cell treatments

Author: Stacey Johnson, 07/14/17

I’ve been thinking about unapproved stem cell treatments a lot recently. First, I read this article that hailed the arrival of stem cell treatments in a small community in western Canada. There were many statements in the article that concerned me, but I only addressed a few major ones in my letter to the editor….Read more

Right Turn: FFB is funding and keeping an eye on vision research

Author: Stacey Johnson, 05/19/17

Dr. Mary Sunderland is quite at ease talking to a video camera. The Director of Research & Education for the Foundation Fighting Blindness (FFB) has been hosting Facebook Live sessions on a variety of topics related to vision research for the past six months. If she was nervous when she began these public outreach sessions…Read more

Major League Baseball Pitchers and “Stem Cell” therapy

Author: David Kent, 04/18/17

With the Toronto Blue Jays* off to a terrible start, I was almost dissuaded from reading anything about baseball, until I happened upon the following article: “Stem-cell therapy is poised to disrupt the Tommy John epidemic in baseball.” First, I had to do my standard “fake news” check by triangulating the sources, readings, etc., but…Read more

From organ survival to organ revival – how patients can regenerate their own donor lung prior to surgery

Author: Holly Wobma, 03/22/17

For most areas of medicine, the supply of a treatment can easily meet demand (access issues aside). Need an antibody? A steroid? Millions of pills are manufactured every day. The case could not be more different for solid organ transplantation, for which the list of patients with end-stage organ failure vastly exceeds the number of…Read more